bioRxivImmunologyPreprint
Virus-like particle displaying SARS-CoV-2 receptor binding domain elicits neutralizing antibodies and is protective in a challenge model
J. L. McKechnie, B. Fiala, C. Wolf, D. Ellis, D. Holtzman, A. Feldhaus
Abstract
While the effort to vaccinate people against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has largely been successful, particularly in the developed world, the rise of new variants as well as waning immunity illustrate the need for a new generation of vaccines that provide broader and/or more durable protection against infection and severe disease. Here we describe the generation and characterization of IVX-411, a computationally designed, two-component virus-like particle (VLP) displaying the ancestral SARS-CoV-2 receptor binding domain (RBD) on its surface. Immunization of mice with IVX-411 generates neutralizing antibodies against the ancestral strain as well as three variants of concern. Neutralizing antibody titers elicited by IVX-411 are durable and significantly higher than those elicited by immunization with soluble RBD and spike antigens. Furthermore, immunization with IVX-411 is shown to be protective in a Syrian Golden hamster challenge model using two different strains of SARS-CoV-2. Overall, these studies demonstrate that IVX-411 is highly immunogenic and capable of eliciting broad, protective immunity.
- organism: mouse
- organism: virus
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A recombinant receptor-binding domain in trimeric form generates completely protective immunity against SARS-CoV-2 infection in nonhuman primates
- Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
A. C. Walls, M. C. Miranda, … Veesler·bioRxiv·Mar 15, 2021
- Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner
F. Amanat, S. Strohmeier, … F. Krammer·bioRxiv·Apr 5, 2021
- SARS-CoV-2 Virus like Particles produced by a single recombinant baculovirus generate potent neutralizing antibody that protects against variant challenge
E. Sullivan, P.-y. Sung, … P. Roy·bioRxiv·Nov 29, 2021
- Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.
D. Kurup, D. C. Malherbe, … M. J. Schnell·bioRxiv·Jan 19, 2021
- Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2